Given the utmost priority of COVID-19 research, many medical journals, especially the leading ones, expedited the review process of these papers. It was expected that the amount of submitted papers for peer review would raise sharply and the deadline of the review period at the COVID-19 outbreak will be tightened. Therefore, sample size calculation of these papers, a component that was being omitted in more than 40% of the published randomized controlled trials,1 might be neglected during the peer review process.
